2024-519060-40-00Not yet recruitingPhase 1
A study of safety, feasibility and immunologic response of transfering tumor infiltrating lymphocytes with or without dendritic cell vaccination in patients with metastatic melanoma
Source: EU CTIS (euclinicaltrials.eu) · Last updated 23 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 22 Jan 2025
- Start date
- 5 Apr 2013
- Lead sponsor
- Karolinska University Hospital
- Diseases
- Melanoma
- EU CT number
- 2024-519060-40-00
- EudraCT number
- 2012-000450-63
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 20
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced melanoma that has spread, with measurable tumours in internal organs. It tests tumour infiltrating lymphocytes with or without a dendritic cell vaccine.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Metastatic malignant melanoma, stage 3 or 4, with measurable lesions in internal organs
Read by machine on 9 Nov 2026.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Karolinska University Hospital | Solna | Sweden | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.